Long Survival after Resection of Small Cell Carcinoma of the Pancreas with Synchronous Adenocarcinoma of the Ampulla of Vater by Liu, Xiaohong et al.
 LiuXHet al. American Journal of Clinical Cancer Research 2013, 1:39-44 
 
Ivy Union Publishing | http: //www.ivyunion.org September 5, 2013 | Volume 1 | Issue 1  
Page 1 of 6 
 
 
Long Survival after Resection of Small 
Cell Carcinoma of the Pancreas with 
Synchronous Adenocarcinoma of the 
Ampulla of Vater 
Xiaohong Liu1,2, Jeffery H. Lee3, Chusilp Charnsangavej4, Ming Geng2, 
Huamin Wang1 
1Department of Pathology, The University of Texas MD Anderson Cancer Center, United States 
2Department of Pathology, General Hospital of Jinan Military Command,Jinan,China 
3Department of Gastroenterology, Hepatology & Nutrition, The University of Texas MD.Anderson Cancer 
Center, United States 
4Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, United States 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords:Small Cell Carcinoma; Pancreas; Adenocarcinoma; Ampulla of Vater 
Peer Reviewers:Radostina Alexandrova, Department of Pathology, Institute of Experimental Morphology, 
Bulgarian Academy of Sciences, Bulgaria; Xiaoning Peng, PhD, Department of Internal Medicine,School of 
Medicine, Hunan Normal University, China 
Received: May 9, 2013; Accepted: July 7, 2013; Published: September 5, 2013 
Competing Interests: The authors have declared that no competing interests exist. 
Consent: Informed consent obtained and was approved by ourinstitutional review board. 
Copyright: 2013Wang Het al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited. 
*Correspondence to: Huamin Wang, Department of Pathology, The University of Texas MD Anderson Cancer 
Center. Email: hmwang@mdanderson.org 
 
 
Abstract  
Introduction: Small cell carcinoma of the pancreas is very rare and the patient usually died within one year 
after diagnosis.  
Presentation of Case: We reported an unusual case of small cell neuroendocrine carcinoma of the pancreas and 
a synchronous moderately differentiated adenocarcinoma of the ampulla of Vater in a 44-year-old male, who 
was successfully treated with pylorus-preserving pancreaticoduodenectomy and post-operative cisplatin-based 
chemoradiation therapy.  
Conclusions: The follow-up data showed no evidence of recurrence and the patient is in a good health 
condition at 117 months after the surgery. 
 
 
 American Journal of  
Clinical Cancer Research 
Case Report 
 
 
American Journals of  
Clinical Cancer Research 
http://ivyunion.org/index.php/ajcre 
Vol. 1, Article ID 20130200152, 6 page
 
 LiuXHet al. American Journal of Clinical Cancer Research 2013, 1:39-44 
 
Ivy Union Publishing | http: //www.ivyunion.org September 5, 2013 | Volume 1 | Issue 1  
Page 2 of 6 
Introduction 
Pancreatic neuroendocrine neoplasms are 
uncommon and represent 1% to 2% of all 
pancreatic neoplasms [1, 2]. In the 2010 World 
Health Organization (WHO) Classification, 
pancreatic neuroendocrine neoplasms are 
classified into well-differentiated [low to 
intermediate grade) neuroendocrine tumor 
(NET) and poorly differentiated (high grade) 
neuroendocrine carcinoma (NEC) based on the 
number of mitoses and/or Ki-67 labeling index 
[1]. Based on this classification, low-grade 
(Grade 1) pancreatic NETs have <2 mitoses 
per 10 high power fields (HPF) and/or ≤2% 
Ki-67 index; intermediate grade (Grade 2) 
pancreatic NETs have 2 to 20 mitoses per 
10HPF and/or 3% to 20% Ki-67 labeling 
index; and high-grade pancreatic NECs have 
>20 mitoses per 10HPF and/or >20% Ki-67 
labeling index [3]. High-grade pancreatic 
NECs are further classified into small cell 
NEC and large cell NEC based on the 
cytologic features [1]. Both small cell NEC 
and large cell NEC of the pancreas are rare 
malignant pancreatic neuroendocrine 
neoplasms and are highly aggressive. Due to 
the rarity of high-grade pancreatic NECs, little 
is known about their biology and clinical 
outcome. Previous studies of high-grade 
pancreatic NECs are mostly case reports and 
small series [1-5]. Patients with high-grade 
pancreatic NEC usually presents at the 
advance stage, which is not resectable at the 
time of diagnosis and virtually all patients died 
within one year of the diagnosis [1-4]. Here, 
we present an unusual case of small cell NEC 
in the head of the pancreas with a synchronous 
adenocarcinoma of ampulla of Vater, who had 
a long survival (117 months) after successful 
pancreaticoduodenectomy and adjuvant 
chemoradiation therapy. 
Case Presentation 
A 44-year-old male presented with painless 
jaundice and a 30 pound weight loss over a 
two-month period. Computed tomographic 
(CT) scan performed at an outside hospital 
demonstrated a large (4.5 cm) tumor in the 
pancreatic head extending into the uncinate 
process and involving the superior mesenteric 
vein (SMV) at the level of the first jejunal 
branch with bulky peripancreatic 
lymphoadenopathy (Figure 1A). The initial 
fine needle aspiration (FNA) biopsy of the 
mass in head of the pancreas performed at the 
outside institution was considered 
non-diagnostic. He also underwent endoscopic 
retrograde cholangiopancreatography (ERCP) 
and endobiliary decompression at local 
hospital which showed an ampullary mass with 
distal biliary stricture. The ampullary biopsy 
showed superficial fragments of atypical 
glandular epithelium suspicious for 
adenocarcinoma. He subsequently underwent a 
staging laparoscopy at outside hospital and 
was found to have no evidence of 
extrapancreatic metastatic disease. Since his 
primary pancreatic tumor involves the superior 
mesenteric vein, he was deemed to have 
locally advanced disease and was referred to 
our institution for second opinion and 
treatment. Due to the radiographic appearances 
of a large primary tumor and prominent 
peripancreatic lymphoadenopathy combined 
with his young age are somewhat unusual for 
pancreatic ductal adenocarcinoma, the 
possibility of a pancreatic neuroendocrine 
carcinoma was clinically considered. 
Endoscopic ultrasound guided FNA of the 
pancreatic head mass was performed and 
showed a poorly differentiated carcinoma with 
neuroendocrine differentiation (positive for 
synaptophysin and chromogranin). He also 
underwent a repeat endoscopy of the upper 
gastrointestinal tract in our hospital. A 
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polypoid mass was identified at the ampulla of 
Vater (Figure 1B). The repeat endoscopic 
biopsy from the ampullary mass showed a 
moderately differentiated adenocarcinoma 
which was negative for both chromogranin and 
synaptophysin. His CA19.9 is 44 U/ml (normal 
0-37U/ml) with a modest elevation in serum 
chromogranin-A (288 ng/ml). All other serum 
tumor markers, including carcinoembryonic 
antigen (CEA), insulin, glucogon, gastrin, and 
pancreatic peptide, were within the normal 
range. He underwent pylorus preserving 
pancreaticoduodenectomy with retroperitoneal 
lymphadenectomy, segmental resection of 
SMV with left internal jugular vein 
interposition graft and cholecystectomy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 A.Computed tomographic (CT) scan showed a 
large mass in the pancreatic head extending into the 
uncinate process and involving the superior mesenteric 
vein (SMV) with peripancreatic lymphoadenopathy. B. 
Endoscopic picture of the mass at the ampulla of Vater. 
Figure 2 Representative micrographs show small cell 
neuroendocrine carcinoma (NEC) of the pancreas with 
infiltrative nodule growth pattern invading the pancreas 
(A), small-sized to medium-sized cells with minimal 
cytoplasm, inconspicuous nucleoli and many mitoses 
(B). The small cell NEC is positive for chromogranin A 
(C) and has Ki-67 labeling index of 60% (D), but is 
negative for retinoblastoma (Rb) protein (E). The 
positive nuclear staining for Rb protein in stromal cells 
serves as internal positive control. Representative 
micrographs shows a moderately differentiated 
adenocarcinoma (intestinal type) of the ampulla of Vater 
arising in a tubular adenoma (F) and the interphase 
between the adenocarcinoma and pancreatic small cell 
NEC in the wall of the duodenum (G). The ampullary 
adenocarcinoma is positive for CDX-2 and pancreatic 
small cell NEC is negative for CDX-2. (Original 
magnifications: 40× for A and G; 200× for B, C and E; 
100× for D, F, and H). 
Gross examination of the 
pancreaticoduodenectomy revealed a tan, firm, 
ill-defined mass (4.5 x 3.5 x 3.2 cm) in the 
head of the pancreas. The pancreatic mass 
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grossly involved the peripancreatic adipose 
tissue and focally involved the duodenal wall, 
invaded into the lumen of the resected segment 
of SMV and obstructed the pancreatic duct, 
but did not involve the common bile duct. In 
addition, a 2.1 x 2.1 cm mass was also 
identified in the ampulla of Vater. The 
ampullary mass grossly invaded into the 
duodenal wall and focally merges with the 
mass in the head of the pancreas. 
Microscopically, the pancreatic mass showed a 
small cell carcinoma with a diffuse, infiltrative 
nodular growth pattern, multiple areas of 
necrosis and brisk mitotic activity (39 
mitoses/10 high power fields, Figure 2A, 2B). 
Tumor invaded into the retroperitoneal 
fibroadipose tissue, the muscularis propria of 
duodenum and the lumen of the resected 
segment of SMV (tumor thrombus), which 
extended to the SMV resection margin 
microscopically. Extensive lymphovascular 
and perineural invasion are present. The tumor 
cells were small to medium in size with 
hyperchromatic nuclei, finely granular 
chromatin pattern, inconspicuous nucleoli and 
scant cytoplasm (Figure 2B). The tumor cells 
were diffusely positive for chromogranin 
(Figure 2C), synaptophysin (data not shown) 
with a Ki-67 labeling index of 60% (Figure 
2D). Therefore the diagnosis of pancreatic 
small cell NEC was rendered. The pancreatic 
small cell NEC was also positive for Bcl-2 and 
was negative for p53 (data not shown), 
retinoblastoma (Rb) protein (Figure 2E) and 
CDX2 (Figure 2H). No adenocarcinoma 
component is identified in the pancreatic mass. 
Sections from the ampullary tumor showed a 
conventional moderately differentiated 
adenocarcinoma (intestinal type) arising in a 
tubular adenoma, which is morphologically 
different from the pancreatic small cell NEC 
(Figure 2F). Both ampullary adenocarcinoma 
and the pancreatic small cell NEC invade into 
the muscularis propria of the duodenum, where 
the two tumors collided. However the 
pancreatic small cell NEC does not involve the 
submucosa or ampullary mucosa and did not 
intermix with the ampullary adenocarcinoma 
(Figure 2G). The ampullary carcinoma is 
negative for chromogranin, synaptophysin, 
p53, and Rb protein, but positive for Bcl-2 and 
CDX-2 (Figure 2H). Metastatic small cell NEC 
was present in 6 of 40 regional lymph nodes 
and all lymph nodes were negative for 
metastatic adenocarcinoma. Therefore the 
diagnosis of small cell NEC of the pancreas 
with synchronous adenocarcinoma of ampulla 
of Vater was rendered in final pathology 
diagnosis. 
Patient recovered uneventfully after the 
surgery and was discharged home on 
postoperative day #8. Postoperatively, he 
received adjuvant radiation therapy (50.4 Gy, 
1.8 Gy/fraction delivered five days per week, 
Monday-Friday, over a period of five and half 
weeks) and total of five cycles of 
chemotherapy consisting of cisplatin (30 
mg/m2) and irinotecan (65mg/m2) on days #1 
and #8 of a 21-day cycle. The patient is doing 
well with no evidence of recurrence or 
metastasis during the follow up of 117 months 
after the surgery. 
Discussion 
Small cell NEC of the pancreas is extremely 
rare. Only few reports have been published 
with fewer than 50 cases reported in the 
English literature [6-13]. This is the first 
reported case of pancreatic small cell NEC 
with synchronous adenocarcinoma of the 
ampulla of Vater, who was successfully treated 
with pancreaticoduodenectomy and adjuvant 
chemoradiation therapy with a long survival. 
According to the previous studies, small cell 
NECs are usually non-functional and are most 
often located in the head of the pancreas with 
an average age of 60 years. Similar to our 
patient, patients with small cell NECs 
commonly present with abdominal pain, 
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jaundice and weight loss[3, 8, 10]. 
Although the adenocarcinoma of ampulla of 
Vater collided focally with the small cell NEC 
of the pancreas in the muscularis propria of 
duodenum in our case, the two tumors had 
distinct morphology and did not intermix with 
each other. The histology of his ampullary 
mass was a moderately differentiated 
adenocarcinoma that was confined in the 
duodenal wall without invasion into the 
pancreatic parenchyma or peripancreatic soft 
tissue. Adenomatous epithelium was present at 
the junction between the ampullary mass and 
the duodenal mucosa, but there is no NEC 
component identified in the entirely submitted 
ampullary mass. On the other hand, the 
pancreatic mass showed a pure small cell NEC 
with no adenocarcinoma component identified 
in 18 sections submitted from the pancreatic 
mass and adjacent pancreatic/peripancreatic 
soft tissue. By immunohistochemistry, the 
pancreatic small cell NEC was diffusely 
positive for chromogranin and synaptophysin 
and was negative for CDX-2. In contrast, the 
adenocarcinoma at the ampulla of Vater is 
diffusely positive for CDX-2 and was negative 
for both chromogranin and synaptophysin. 
Thus it is less likely that pancreatic small cell 
NEC is arising from the adenocarcinoma of the 
ampulla of Vater.  
The origin of high-grade NECs of the 
pancreas is uncertain. Although it is possible 
that well-differentiated pancreatic NET may 
rarely transform into a high-grade pancreatic 
NECs and pancreatic ductal carcinoma 
(PDAC) may also give arise to high grade 
pancreatic NEC, recent genetic and 
immunohistochemical study by Yachida et al 
suggest that high-grade pancreatic NECs are 
distinct from well-differentiated pancreatic 
NETs as well as pancreatic ductal 
adenocarcinoma (PDAC), but have a similar 
profile in the genetic alterations to the small 
cell carcinoma of lung [10]. Many genetic 
alterations that are characteristic for PDAC, 
such as activating Kras mutations and loss of 
CDKN2A/p16 and SMAD4/DPC4, are 
infrequently found in high-grade pancreatic 
NECs [3, 10, 14]. In contrast to 
well-differentiated pancreatic NETs which 
have no mutations in p53 or Rb genes, 
mutations in p53 and Rb genes are identified 
in 100% and 89% respectively in the small cell 
NECs of the pancreas; 90% and 60% 
respectively in large cell NECs of the pancreas. 
High-grade pancreatic NECs also have higher 
frequency of Bcl-2 overexpression than 
PDACs or well differentiated NETs in their 
study [10]. Consistent with their study, the 
pancreatic small cell NEC in our case was 
positive for Bcl-2 and lost expression of Rb 
protein. However our case is negative for p53 
by immunohistochemistry. 
Pancreatic small cell NEC is a highly 
aggressive neoplasm with a dismal prognosis 
and patient usually died within 1 year after 
diagnosis[3, 8, 10], except three cases reports 
of 36, and 56 and 173 months of survival after 
surgery [11-13]. Recent study conducted by 
Winter et al showed that patients with 
pancreatic small cell NEC may benefit from 
post-operative cisplatin and etoposide-based 
chemoradiation therapy [13]. Our patient was 
successfully treated with 
pancreaticoduodenectomy and adjuvant 
cisplatin-based chemoradiation and was alive 
with no evidence of disease at 117 months. 
Given the limited number of cases in these 
studies, further studies are needed to identify 
effective treatment for small cell NEC of the 
pancreas. 
Conclusions   
We reported an unusual case of small cell 
neuroendocrine carcinoma of the pancreas 
with a synchronous moderately differentiated 
adenocarcinoma of the ampulla of Vater, who 
was successfully treated with surgery and 
adjuvant cisplatin-based chemoradiation 
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therapy and was disease-free at 117 months 
after the surgery. 
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